These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 33771522)

  • 1. MiR-221-3p-mediated downregulation of MDM2 reverses the paclitaxel resistance of non-small cell lung cancer in vitro and in vivo.
    Ni L; Xu J; Zhao F; Dai X; Tao J; Pan J; Shi A; Shen Z; Su C; Zhang Y
    Eur J Pharmacol; 2021 May; 899():174054. PubMed ID: 33771522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of hsa_circ_0002874 promotes resistance of non-small cell lung cancer to paclitaxel by modulating miR-1273f/MDM2/p53 pathway.
    Xu J; Ni L; Zhao F; Dai X; Tao J; Pan J; Shi A; Shen Z; Su C; Zhang Y
    Aging (Albany NY); 2021 Feb; 13(4):5986-6009. PubMed ID: 33612481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of miR-4262 in paclitaxel resistance through the regulation of PTEN in non-small cell lung cancer.
    Sun H; Zhou X; Bao Y; Xiong G; Cui Y; Zhou H
    Open Biol; 2019 Jul; 9(7):180227. PubMed ID: 31337279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells.
    Park SH; Seong MA; Lee HY
    Oncotarget; 2016 Feb; 7(7):8184-99. PubMed ID: 26799187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
    Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
    Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circ_0011292 knockdown mitigates progression and drug resistance in PTX-resistant non-small-cell lung cancer cells by regulating miR-433-3p/CHEK1 axis.
    Jin M; Zhang F; Li Q; Xu R; Liu Y; Zhang Y
    Thorac Cancer; 2022 May; 13(9):1276-1288. PubMed ID: 35348291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. circ_0007385 served as competing endogenous RNA for miR-519d-3p to suppress malignant behaviors and cisplatin resistance of non-small cell lung cancer cells.
    Ye Y; Zhao L; Li Q; Xi C; Li Y; Li Z
    Thorac Cancer; 2020 Aug; 11(8):2196-2208. PubMed ID: 32602212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dysregulated
    Sui J; Zhao Q; Zhang Y; Liang G
    DNA Cell Biol; 2022 Mar; 41(3):319-329. PubMed ID: 35244469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced miR-363-3p expression in non-small cell lung cancer is associated with gemcitabine resistance via targeting of CUL4A.
    Bian WG; Zhou XN; Song S; Chen HT; Shen Y; Chen P
    Eur Rev Med Pharmacol Sci; 2019 Jan; 23(2):649-659. PubMed ID: 30720173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long non-coding RNA XIST expedites lung adenocarcinoma progression through upregulating MDM2 expression via binding to miR-363-3p.
    Rong H; Chen B; Wei X; Peng J; Ma K; Duan S; He J
    Thorac Cancer; 2020 Mar; 11(3):659-671. PubMed ID: 31968395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NORAD accelerates chemo-resistance of non-small-cell lung cancer via targeting at miR-129-1-3p/SOX4 axis.
    Huang Q; Xing S; Peng A; Yu Z
    Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31894841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TNFAIP8 promotes the proliferation and cisplatin chemoresistance of non-small cell lung cancer through MDM2/p53 pathway.
    Xing Y; Liu Y; Liu T; Meng Q; Lu H; Liu W; Hu J; Li C; Cao M; Yan S; Huang J; Wang T; Cai L
    Cell Commun Signal; 2018 Jul; 16(1):43. PubMed ID: 30064446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LncRNA MALAT1 Depressed Chemo-Sensitivity of NSCLC Cells through Directly Functioning on miR-197-3p/p120 Catenin Axis.
    Yang T; Li H; Chen T; Ren H; Shi P; Chen M
    Mol Cells; 2019 Mar; 42(3):270-283. PubMed ID: 30841025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-339-5p downregulation contributes to Taxol resistance in small-cell lung cancer by targeting α1,2-fucosyltransferase 1.
    Gan CZ; Li G; Luo QS; Li HM
    IUBMB Life; 2017 Nov; 69(11):841-849. PubMed ID: 28940895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
    Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS
    J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-186 regulates chemo-sensitivity to paclitaxel via targeting MAPT in non-small cell lung cancer (NSCLC).
    Ye J; Zhang Z; Sun L; Fang Y; Xu X; Zhou G
    Mol Biosyst; 2016 Oct; 12(11):3417-3424. PubMed ID: 27714074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blocking hsa_circ_0074027 suppressed non-small cell lung cancer chemoresistance via the miR-379-5p/IGF1 axis.
    Zheng S; Wang C; Yan H; Du Y
    Bioengineered; 2021 Dec; 12(1):8347-8357. PubMed ID: 34592879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mir-660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interaction.
    Fortunato O; Boeri M; Moro M; Verri C; Mensah M; Conte D; Caleca L; Roz L; Pastorino U; Sozzi G
    Cell Death Dis; 2014 Dec; 5(12):e1564. PubMed ID: 25501825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Luteolin Inhibits Tumorigenesis and Induces Apoptosis of Non-Small Cell Lung Cancer Cells via Regulation of MicroRNA-34a-5p.
    Jiang ZQ; Li MH; Qin YM; Jiang HY; Zhang X; Wu MH
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29393891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-137 inhibits tumor growth and sensitizes chemosensitivity to paclitaxel and cisplatin in lung cancer.
    Shen H; Wang L; Ge X; Jiang CF; Shi ZM; Li DM; Liu WT; Yu X; Shu YQ
    Oncotarget; 2016 Apr; 7(15):20728-42. PubMed ID: 26989074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.